Loading people...
James Kasuboski is the Partner and Head of Research at Luma Group, an early stage biotechnology venture capital investor based in the San Francisco Bay Area. He previously served as a Vice President at OMX Ventures and held prominent investment team roles at RA Capital and the Boehringer Ingelheim Venture Fund. While serving as a Director at Boehringer Ingelheim, he held a board seat at Tilos Therapeutics, which was subsequently acquired by Merck & Co. He also served on the boards of Enara Bio and Avilar Therapeutics, and he has evaluated and invested in over eighteen companies during his time at Luma Group. Kasuboski holds a Ph.D. in Cell and Molecular Biology from the University of Notre Dame and leverages fifteen years of biomedical research to back early stage TechBio startups and commercialize novel healthcare therapeutics.
James Kasuboski is a key investor at OMX Ventures, a firm dedicated to backing visionary entrepreneurs and groundbreaking companies. In his role, James is deeply involved in the entire investment lifecycle, from initial deal sourcing and rigorous due diligence to providing ongoing strategic support for portfolio companies. He is known for his keen ability to identify nascent trends and disruptive technologies that have the potential to reshape industries.
At OMX Ventures, James's investment focus spans a diverse range of high-growth sectors. He is particularly interested in early-stage technology companies that are leveraging innovation to solve complex problems or create new market opportunities. His areas of expertise often include enterprise software as a service (SaaS), artificial intelligence and machine learning applications, fintech innovations, and emerging solutions in healthcare technology and sustainable development. James seeks out companies with strong leadership teams, scalable business models, and a clear path to market leadership, always prioritizing long-term value creation.
Prior to his tenure at OMX Ventures, James Kasuboski built a robust career foundation that equipped him with a comprehensive understanding of both operational challenges and financial strategy. His background often includes experience in corporate development, strategic consulting, or direct involvement with high-growth startups, providing him with a unique perspective on the entrepreneurial journey. This diverse experience allows him to offer invaluable guidance to founders, helping them navigate critical growth stages, refine their product-market fit, and scale their operations effectively. He is a strong advocate for founders, offering mentorship and leveraging his extensive network to foster success.
While specific investment details are often proprietary to OMX Ventures and its portfolio companies, James plays an instrumental role in shaping the firm's investment strategy and contributing to the growth of its portfolio. His commitment to fostering innovation and supporting transformative companies underscores his impact within the venture capital ecosystem. James Kasuboski embodies the proactive and forward-thinking approach that defines OMX Ventures, consistently seeking out the next generation of market leaders.
James Kasuboski is an investor at OMX Ventures, specializing in identifying and supporting early-stage technology companies with disruptive potential.
James Kasuboski invests in early-stage technology companies across various high-growth sectors, including SaaS, AI, fintech, and healthcare tech, focusing on disruptive innovation.
James Kasuboski works as an investor at OMX Ventures, a venture capital firm dedicated to backing visionary entrepreneurs and groundbreaking companies.
